OncoSil Medical's (ASX:OSL) managing director Daniel Kenny talks pathway to CE Mark approval with Proactive Investors.
OncoSil's lead product candidate is the OncoSil™ medical device, which is focussed on localised radiation treatment for cancer.
OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment.
The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.